EPIRUS BIOPHARMACEUTICALS
EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.
EPIRUS BIOPHARMACEUTICALS
Social Links:
Industry:
Biotechnology Life Science Therapeutics
Founded:
2000-03-28
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.epirusbiopharma.com
Total Employee:
11+
Status:
Active
Contact:
6176073437
Email Addresses:
[email protected]
Total Funding:
83.08 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Font Awesome Domain Not Resolving Sitelinks Search Box Organization Schema Yoast WordPress SEO Plugin Google Maps
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-09-09 | Bioceros | Bioceros acquired by Epirus Biopharmaceuticals | 14.1 M USD |
| 2014-07-15 | Zalicus | Zalicus acquired by Epirus Biopharmaceuticals | N/A |
Investors List
Livzon Mabpharm
Livzon Mabpharm investment in Series B - Epirus Biopharmaceuticals
TPG Biotech
TPG Biotech investment in Series B - Epirus Biopharmaceuticals
5AM Ventures
5AM Ventures investment in Series B - Epirus Biopharmaceuticals
Mousse Partners
Mousse Partners investment in Series B - Epirus Biopharmaceuticals
Greenwoods Investment
Greenwoods Investment investment in Series B - Epirus Biopharmaceuticals
Montreux Equity Partners
Montreux Equity Partners investment in Series B - Epirus Biopharmaceuticals
Gibralt Capital Corporation
Gibralt Capital Corporation investment in Series B - Epirus Biopharmaceuticals
Adage Capital Management
Adage Capital Management investment in Series B - Epirus Biopharmaceuticals
5AM Ventures
5AM Ventures investment in Venture Round - Epirus Biopharmaceuticals
Montreux Equity Partners
Montreux Equity Partners investment in Venture Round - Epirus Biopharmaceuticals
Official Site Inspections
http://www.epirusbiopharma.com
- Host name: epirusbiopharma.com
- IP address: 162.243.32.126
- Location: New York United States
- Latitude: 40.7308
- Longitude: -73.9975
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10011
More informations about "Epirus Biopharmaceuticals"
Epirus Biopharmaceuticals - Crunchbase Company …
Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.See details»
Epirus Biopharmaceuticals - CB Insights
Epirus is building a global biosimilar enterprise to improve patient access to important medicines. The Company's strategy for commercial success relies on targeted approaches for diverse …See details»
EPIRUS Biopharmaceuticals Inc - Company Profile and News
Company profile page for EPIRUS Biopharmaceuticals Inc including stock price, company news, executives, board members, and contact informationSee details»
EPIRUS Biopharmaceuticals, Inc.
Explore EPIRUS Biopharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 23 clinical trials, 15 news, and 35 literature, Disease Domain ...See details»
Epirus Biopharma - Company Profile - Tracxn
Sep 19, 2024 Epirus Biopharma - Develops biosimilar monoclonal antibodies and therapeutic proteins. Public Company. Raised a total funding of $44.5M over 4 rounds from 16 investors.See details»
EPIRUS Biopharmaceuticals - Business Information - ZoomInfo
View EPIRUS Biopharmaceuticals (www.epirusbiopharma.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as …See details»
About EPIRUS - Epirus News
At Epirus we believe the informed use of pharmaceuticals and similar health supplements can be a helpful tool to increase mental and physical health, as well as success in all aspects of life …See details»
Epirus Biopharmaceuticals - M&A Summary and Business …
Epirus Biopharmaceuticals’ largest acquisition to date was in 2015, when it acquired Bioceros BV for $14M. It’s largest disclosed sale occurred in 2015, when it sold Zalicus Pharmaceuticals to …See details»
Epirus Biopharmaceuticals - VentureRadar
Oncobiologics is a privately-held biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 …See details»
EPIRUS Biopharmaceuticals Joins Biosimilars Forum To Help …
Nov 5, 2015 For more information visit EPIRUS’ website at www.epirusbiopharma.com. About the Biosimilars Forum The Biosimilars Forum is a nonprofit organization whose mission is to …See details»
EPIRUS Biopharmaceuticals, Inc. | Insights
Latest on EPIRUS Biopharmaceuticals, Inc. Already A Biomedtracker Subscriber?You have access to the full company record through your subscription.See details»
Boston-Based EPIRUS Biopharmaceuticals Reels In $36 Million
Apr 16, 2014 BOSTON--Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of …See details»
Epirus Biopharmaceuticals - Contacts, Employees, Board Members ...
Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.See details»
Epirus Biopharmaceuticals : and Polpharma Group Enter Into a …
Jul 14, 2015 "This profit-sharing collaboration with Polpharma Group enables us to better direct our business and retain future value," said Amit Munshi, president and chief executive officer, …See details»
Epirus grabs $36 mln Series B funds and merges with Zalicus
Apr 16, 2014 Epirus Biopharmaceuticals said Wednesday that it has secured $36 million in Series B funding. Livzon Mabpharm led the round with participation from other investors that …See details»
EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and …
BOSTON, Sept. 09, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and …See details»
EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and …
BOSTON, Sept. 09, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and …See details»
Epirus and Zalicus Announce Merger Agreement - Business Wire
Apr 16, 2014 After an extensive review of potential merger candidates and their product pipelines, Zalicus identified Epirus as an organization with the potential to create significant …See details»
EPIRUS Announces Reprioritization of Pipeline to Solely Focus on ...
BOSTON, May 09, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and …See details»
Epirus files for bankruptcy protection and hands Remicade biosim …
Jul 26, 2016 Epirus Biopharmaceuticals has filed for Chapter 7 bankruptcy protection, settled with licensee Livzon Mabpharm and handed its Remicade (infliximab) biosimilar to Reliance …See details»